Literature DB >> 23325838

Pharmacological inhibition of VIP signaling enhances antiviral immunity and improves survival in murine cytomegalovirus-infected allogeneic bone marrow transplant recipients.

Jian-Ming Li1, Mohammad S Hossain, Lauren Southerland, Edmund K Waller.   

Abstract

Cytomegalovirus (CMV) infection following allogeneic bone marrow transplant (allo-BMT) is controlled by donor-derived cellular immunity. Vasoactive intestinal peptide (VIP) suppresses Th1 immunity. We hypothesized that blocking VIP-signaling would enhance anti-CMV immunity in murine recipients of allo-BMT. Recipients were transplanted with bone marrow (BM) and T-cells from major histocompatibility complex (MHC)-mismatched VIP-knockout (KO) or wild-type donors, and treated with 7 daily subcutaneous injections of VIPhyb (peptidic VIP-antagonist) or phosphate-buffered saline (PBS). Genetic and pharmacological blockade of VIP-signaling protected allo-BMT recipients from lethal murine CMV (mCMV) infection, improving survival without increasing graft-versus-host disease. Mice treated with VIPhyb or transplanted with VIP-KO allografts had significantly lower viral loads, increased numbers of mCMV-M45-peptide-MHC-tetramer(+) CD8(+) T-cells, with lower PD-1 expression, and enhanced primary and secondary cellular immune responses after mCMV infection than did PBS-treated mice. These results demonstrate that administration of a VIP antagonist after allo-BMT is a promising safely therapeutic approach to enhance antiviral cellular immunity.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23325838      PMCID： PMC3606069          DOI： 10.1182/blood-2012-06-437640

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  25 in total

Review 1.  The significance of vasoactive intestinal peptide in immunomodulation.

Authors:  Mario Delgado; David Pozo; Doina Ganea
Journal:  Pharmacol Rev       Date:  2004-06       Impact factor: 25.468

2.  Lymphoid cell subpopulations containing vasoactive intestinal peptide in the rat.

Authors:  J Leceta; M C Martinez; M Delgado; E Garrido; R P Gomariz
Journal:  Peptides       Date:  1994       Impact factor: 3.750

Review 3.  A VIP hybrid antagonist: from developmental neurobiology to clinical applications.

Authors:  I Gozes; M Fridkin; D E Brenneman
Journal:  Cell Mol Neurobiol       Date:  1995-12       Impact factor: 5.046

4.  An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin.

Authors:  K R Cooke; L Kobzik; T R Martin; J Brewer; J Delmonte; J M Crawford; J L Ferrara
Journal:  Blood       Date:  1996-10-15       Impact factor: 22.113

5.  IFN-γ and indoleamine 2,3-dioxygenase signaling between donor dendritic cells and T cells regulates graft versus host and graft versus leukemia activity.

Authors:  Ying Lu; Cynthia R Giver; Akshay Sharma; Jian Ming Li; Katarzyna A Darlak; Lauren M Owens; John D Roback; Jacques Galipeau; Edmund K Waller
Journal:  Blood       Date:  2011-11-30       Impact factor: 22.113

6.  Irradiated donor leukocytes promote engraftment of allogeneic bone marrow in major histocompatibility complex mismatched recipients without causing graft-versus-host disease.

Authors:  E K Waller; A M Ship; S Mittelstaedt; T W Murray; R Carter; I Kakhniashvili; S Lonial; J T Holden; M W Boyer
Journal:  Blood       Date:  1999-11-01       Impact factor: 22.113

7.  Vasoactive intestinal polypeptide and somatostatin in leucocytes.

Authors:  I Lygren; A Revhaug; P G Burhol; K E Giercksky; T G Jenssen
Journal:  Scand J Clin Lab Invest       Date:  1984-06       Impact factor: 1.713

Review 8.  Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies.

Authors:  Michael Boeckh; W Garrett Nichols; Genovefa Papanicolaou; Robert Rubin; John R Wingard; John Zaia
Journal:  Biol Blood Marrow Transplant       Date:  2003-09       Impact factor: 5.742

9.  Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.

Authors:  Jian-Ming Li; Edmund K Waller
Journal:  Biol Blood Marrow Transplant       Date:  2004-08       Impact factor: 5.742

10.  VIP gene expression in rat thymus and spleen.

Authors:  R P Gomariz; M Delgado; J R Naranjo; B Mellström; A Tormo; F Mata; J Leceta
Journal:  Brain Behav Immun       Date:  1993-12       Impact factor: 7.217
View more
  6 in total

1.  Administration of a vasoactive intestinal peptide antagonist enhances the autologous anti-leukemia T cell response in murine models of acute leukemia.

Authors:  Christopher T Petersen; Jian-Ming Li; Edmund K Waller
Journal:  Oncoimmunology       Date:  2017-03-16       Impact factor: 8.110

2.  Modulation of Immune Checkpoints and Graft-versus-Leukemia in Allogeneic Transplants by Antagonizing Vasoactive Intestinal Peptide Signaling.

Authors:  Jian-Ming Li; Christopher T Petersen; Jing-Xia Li; Reema Panjwani; Daniel J Chandra; Cynthia R Giver; Bruce R Blazar; Edmund K Waller
Journal:  Cancer Res       Date:  2016-09-26       Impact factor: 12.701

3.  Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3Kδ inhibitors and VIP antagonists.

Authors:  Christopher T Petersen; Mojibade Hassan; Anna B Morris; Jasmin Jeffery; Kunhee Lee; Neera Jagirdar; Ashley D Staton; Sunil S Raikar; Harold T Spencer; Todd Sulchek; Christopher R Flowers; Edmund K Waller
Journal:  Blood Adv       Date:  2018-02-13

4.  PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients.

Authors:  Mohammad S Hossain; Ghada M Kunter; Vicky F El-Najjar; David L Jaye; Zaid Al-Kadhimi; Owonikoko K Taofeek; Jian-Ming Li; Edmund K Waller
Journal:  PLoS One       Date:  2017-09-27       Impact factor: 3.240

5.  VIPhyb, an antagonist of vasoactive intestinal peptide receptor, enhances cellular antiviral immunity in murine cytomegalovirus infected mice.

Authors:  Jian-Ming Li; Kasia A Darlak; Lauren Southerland; Mohammad S Hossain; David L Jaye; Cassandra D Josephson; Hilary Rosenthal; Edmund K Waller
Journal:  PLoS One       Date:  2013-05-27       Impact factor: 3.240

6.  Recombinant TLR5 agonist CBLB502 promotes NK cell-mediated anti-CMV immunity in mice.

Authors:  Mohammad S Hossain; Sampath Ramachandiran; Andrew T Gewirtz; Edmund K Waller
Journal:  PLoS One       Date:  2014-05-30       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.